Quantifying the carcinogenicity of antineoplastic drugs

European Journal of Cancer and Clinical Oncology

Volumn 24, Issue 4, 1988, Pages 703-711

  Kaldor, John M ^a   Day, Nicholas E ^b   Hemminki, Kari ^c  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CARCINOGENICITY; HUMAN; MOUSE; NONHUMAN; RAT; SIDE EFFECT; THEORETICAL STUDY;

ANIMAL; ANTINEOPLASTIC AGENTS; FEMALE; LEUKEMIA; MALE; MICE; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RATS; RISK FACTORS;

EID: 0023920752     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(88)90302-1     Document Type: Article

References (35)

1. Risk of new cancers in patients with Hodgkin's disease
2. Leukemia and other cancers after radiotherapy and chemotherapy for Hodgkin's disease
3. Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma
4. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphoma
5. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer—a study of five randomized trials
6. Melphalan may be a more potent leukemogen than is cyclophosphamide
7. Acute leukemia after chemotherapy (melphalan)
8. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia
9. Long-term survival in myelomatosis
10. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung
11. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy
12. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide
13. Melphalan-related leukemia in multiple myeloma
14. Acute leukaemia after busulphan
15. Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with treosulfan (=dihydroxybusulfan)
16. Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU)
17. Curability of advanced Hodgkin's disease with chemotherapy: long-term follow-up of MOPP-treated patients at the National Cancer Institute
18. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSAPB experience
19. A carcinogenic potency database of the standardized results of animal bioassay
20. An empirical comparison of methods used to estimate carcinogenic potency in long-term animal bioassays: lifetable vs. summary incidence data
21. 50: a proposed general convention for the numerical description of the carcinogenic potency of chemicals in chronic exposure animal experiments
22. Experimentelle Untersuchungen über carcinogene Wirkungen von Krebs-Chemotherapeutica und Immunosuppressiva
23. Life-span carcinogenicity tests with 4-amino-N-(10)-methylpteroylglutamic acid (methotrexate) in Swiss mice and Syrian golden hamsters
24. Life-span investigations for carcinogenicity of some immune-stimulating, immunodepressive and neurotropic substances in Sprague-Dawley rats
25. Bioassay program for carcinogenic hazards of cancer chemotherapeutic agents
26. Stereochemistry of actinomycin-DNA binding
27. Some tautologous aspects of the comparison of carcinogenic potency in rats and mice
28. Interspecies comparison of carcinogenic potency
29. Regulating Pesticides
30. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries